Lilly Asia Ventures took part in a series B-plus round that marks the first for biopharmaceutical company Transcenta Holding, formed through the merger of two of the corporate's portfolio companies.
China-based biopharmaceuticals developer Transcenta Holding has received $100m in a series B-plus round featuring Lilly Asia Ventures, the Asia-focused corporate venturing vehicle for pharmaceutical firm Eli Lilly.
The round was co-led by CR-CP Life Science Fund and Fortune Capital, while Temasek, Epiphron Capital, CCT China Merchant Buyout Fund, China Equity Group, Hillhouse Capital, Teng Yue Partners, Sequoia Capital and Arch Venture Partners also took part.
Transcenta is working on antibody-driven drugs for cancer, kidney disease and bone disorders. It was…
